Diligence memo · auto-generated · as of July 2, 2026

S4 Medical Corp.

S4 Medical Corp. looks fair against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

S4 Medical Corp. operates in Biotechnology, based in CHAGRIN FALLS.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

S4 Medical Corp. has raised $12M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $5.8M on 2023-06-23.

Most recent recorded round closed around 2023-06-23.

Valuation (modeled)modeled

Provath models S4 Medical Corp. at approximately $50M (range $6.3M–$136M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 1.12× the median modeled value of Series A Biotechnology companies in 2022–2024 (303 peers) — value vs value, same stage and era. Within the normal band (112% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 13 months.

Last raise 3.0 yr ago; this sector typically re-raises about every 14 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round stepped up 7.7× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 59% of Biotechnology peers (4293 compared).

Modeled value ranks above 45% of those peers.

Closest niche peers: GeoVax Labs, Inc., Cellinfinity Bio Holding Company, LLC, Adient Medical, Inc., Entegrion Inc, BCD Bioscience, Inc..

Peoplefiled

9 named people on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.